Thrombotic Microangiopathy after Allogeneic Blood and Marrow Transplantation Is Associated with Dose-Intensive Myeloablative Conditioning Regimens, Unrelated Donor, and Methylprednisolone T-Cell Depletion
Theresa Hahn(Roswell Park Comprehensive Cancer Center), Philip L. McCarthy(Roswell Park Comprehensive Cancer Center), Meir Wetzler, Maria R. Baer(University of Maryland, Baltimore), Arif Alam(Roswell Park Comprehensive Cancer Center), L. Ford(Roswell Park Comprehensive Cancer Center), Barbara Bambach(Roswell Park Comprehensive Cancer Center), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), James L. Slack(Memorial Sloan Kettering Cancer Center), David Lawrence(VA Connecticut Healthcare System), Joanne Becker(Roswell Park Comprehensive Cancer Center), Zale P. Bernstein(Hemophilia Center of Western Pennsylvania), Joaquín Silva(Roswell Park Comprehensive Cancer Center)
Cited by 38
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k